<DOC>
	<DOCNO>NCT00737932</DOCNO>
	<brief_summary>The study aim evaluate safety clinical effect daily oral treatment Laquinimod capsule active moderate severe Crohn 's disease . This study ass Laquinimod dose 0.5mg /day 2 mg/day sequential dose group ( cohort ) . Laquinimod novel immunomodulating drug currently advance stage development Teva Pharmaceuticals Ltd. Multiple Sclerosis .</brief_summary>
	<brief_title>Laquinimod Phase IIa Study Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Subjects diagnose Crohn 's disease least 3 month prior screen . 2 . Moderate severe Crohn 's disease patient determine CDAI score 1 . Subjects recent bowel surgery 2 . Subjects clinically significant GI obstructive symptom 3 . Subjects clinically significant unstable medical surgical condition 4 . Subjects unstable dos standard care medication ( 5ASA , antibiotic , oral corticosteroid , immunosuppressant ) 5 . Women pregnant nursing intend study period . 6 . Women childbearing potential practice acceptable method birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>